Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2025 21:17 ET | Source: Robbins LLP

BIOA STOCK NEWS: Robbins LLP Reminds BioAge Labs, Inc. Investors of the Pending Lead Plaintiff Deadline – March 10, 2025

Robbins LLP is Investigating Allegations that BioAge Labs, Inc. (BIOA) Misled Investors Regarding its Lead Drug Candidate in Connection with its IPO
February 18, 2025 21:10 ET | Source: Robbins LLP

TransMedics Group, Inc. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against TMDX

Robbins LLP is Investigating Allegations that TransMedics Group, Inc. (TMDX) Misled Investors Regarding its Coercive and Unsafe Business Practices
February 18, 2025 20:09 ET | Source: Robbins LLP

Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK

Robbins LLP is Investigating Allegations that Merck & Co., Inc. (MRK) Misled Investors Regarding the Projected Revenue Outlook and Growth of Gardasil
February 14, 2025 17:51 ET | Source: Robbins LLP

NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S

Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity
February 14, 2025 17:33 ET | Source: Robbins LLP

EPIX STOCK NEWS: EPIX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Essa Pharma Inc.

Robbins LLP is Investigating Allegations that ESSA Pharma Inc. (EPIX) Misled Investors Regarding the Efficacy of its Drug Candidate Masofaniten
February 11, 2025 19:18 ET | Source: Robbins LLP

ModivCare, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the MODV Class Action Lawsuit

Robbins LLP is Investigating Allegations that ModivCare, Inc. (MODV) Misled Investors Regarding its Business Prospects
February 03, 2025 20:38 ET | Source: Robbins LLP

ModivCare, Inc. Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against MODV

Robbins LLP is Investigating Allegations that ModivCare, Inc. (MODV) Misled Investors Regarding its Business Prospects
January 28, 2025 15:19 ET | Source: Robbins LLP

NVO Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Novo Nordisk A/S

Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity
January 28, 2025 15:14 ET | Source: Robbins LLP

EPIX Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against ESS Pharma Inc.

Robbins LLP is Investigating Allegations that ESSA Pharma Inc. (EPIX) Misled Investors Regarding the Efficacy of its Drug Candidate Masofaniten
January 24, 2025 16:01 ET | Source: Robbins LLP

Kyverna Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Class Action Against KYTX

Robbins LLP is Investigating Allegations that Kyverna Therapeutics, Inc. (KYTX) Provided Investors with Misleading Information in Connection with its IPO

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right